Ending AIDS deaths requires improvements in clinical care for people with advanced HIV disease who are seriously ill.
Journal
The lancet. HIV
ISSN: 2352-3018
Titre abrégé: Lancet HIV
Pays: Netherlands
ID NLM: 101645355
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
13
02
2023
revised:
12
04
2023
accepted:
04
05
2023
medline:
10
7
2023
pubmed:
11
6
2023
entrez:
10
6
2023
Statut:
ppublish
Résumé
Over 4 million adults are living with advanced HIV disease with approximately 650 000 fatalities from HIV reported in 2021. People with advanced HIV disease have low immunity and can present to health services in two ways: those who are well but at high risk of developing severe disease, and those who are severely ill. These two groups require specific management approaches that place different demands on the health system. The first group can generally be supported in primary care settings but require differentiated care to meet their needs. The second group are at high risk of death and need focused diagnostics and clinical care, and possibly hospitalisation. Investments in high-quality clinical management of patients with advanced HIV disease who are seriously ill at primary care or hospital level (often only for a brief period of time during their acute illness) improves the likelihood that their condition will stabilise and that they will recover. Providing high-quality and safe clinical care that is accessible to these groups of people living with HIV who are at risk of severe illness and death is a key priority for reaching the global target of zero AIDS deaths.
Identifiants
pubmed: 37301220
pii: S2352-3018(23)00109-1
doi: 10.1016/S2352-3018(23)00109-1
pmc: PMC7614731
mid: EMS177217
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e482-e484Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Informations de copyright
Copyright © 2023 World Health Organization. Published by Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests We declare no competing interests.
Références
Lancet. 2018 Jul 28;392(10144):292-301
pubmed: 30032978
AIDS. 2021 Nov 1;35(13):2191-2199
pubmed: 34172671
Lancet Infect Dis. 2018 Oct;18(10):1150-1159
pubmed: 30146320
Lancet Glob Health. 2021 Nov;9(11):e1618-e1622
pubmed: 34678201
Lancet HIV. 2015 Oct;2(10):e438-44
pubmed: 26423651
Lancet. 2016 Mar 19;387(10024):1198-209
pubmed: 27025337
PLOS Glob Public Health. 2023 Feb 22;3(2):e0001557
pubmed: 36963024
PLoS One. 2018 Mar 15;13(3):e0192991
pubmed: 29543818
N Engl J Med. 2022 Mar 24;386(12):1109-1120
pubmed: 35320642
Wellcome Open Res. 2018 Mar 20;3:31
pubmed: 30320225
Lancet HIV. 2020 Jan;7(1):e27-e37
pubmed: 31727580
Lancet. 2016 Mar 19;387(10024):1187-97
pubmed: 26970721
N Engl J Med. 2017 Jul 20;377(3):233-245
pubmed: 28723333
Clin Infect Dis. 2018 Mar 4;66(suppl_2):S152-S159
pubmed: 29514236
Lancet HIV. 2022 Mar;9(3):e150-e159
pubmed: 35245507
Lancet Infect Dis. 2022 Dec;22(12):1748-1755
pubmed: 36049486
Lancet. 2015 May 30;385(9983):2173-82
pubmed: 25765698
N Engl J Med. 2020 Jun 18;382(25):2397-2410
pubmed: 32558469
Health Sci Rep. 2023 Feb 22;6(2):e1124
pubmed: 36846535
Clin Infect Dis. 2016 Apr 1;62(7):935-944
pubmed: 26679625
Lancet Infect Dis. 2018 Mar;18(3):e76-e86
pubmed: 29066132
Am J Trop Med Hyg. 2021 Oct 18;105(6):1662-1671
pubmed: 34662866